Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants With Active Rheumatoid Arthritis Despite Standard Therapy

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants With Active Rheumatoid Arthritis Despite Standard Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nipocalimab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IRIS-RA
  • Sponsors Janssen Research & Development

Most Recent Events

  • 15 Nov 2023 Primary endpoint (Change from Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12) has not been met according to Results presented at the ACR Convergence 2023.
  • 15 Nov 2023 Results assessing efficacy and safety of nipocalimab in patients with moderate to severe, active RA presented at the ACR Convergence 2023
  • 07 Nov 2023 According to a Johnson & Johnson media release, data from this study will be presented at ACR Convergence 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top